Priliximab

Priliximab (cMT 412) is a human-mouse chimeric anti-CD4 monoclonal antibody. It has been tested on patients with Crohn's disease^[1] and multiple sclerosis^[2][3] but has not yet received U.S. Food and Drug Administration licensing. The patent belongs to the biotechnology company Centocor.

Priliximab

Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	CD4
Clinical data
ATC code	none
Identifiers
CAS Number	147191-91-1 N
ChemSpider	none
UNII	TW5DE23BLM
NY (what is this?)  (verify)